Mon, August 28, 2023

Salim Syed Reiterated (BBIO) at Strong Buy and Held Target at $60 on, Aug 28th, 2023

Salim Syed of Mizuho, Reiterated "BridgeBio Pharma, Inc." (BBIO) at Strong Buy and Held Target at $60 on, Aug 28th, 2023.

Salim has made no other calls on BBIO in the last 4 months.



There are 4 other peers that have a rating on BBIO. Out of the 4 peers that are also analyzing BBIO, 1 agrees with Salim's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Eun Yang of "Jefferies" Downgraded from Strong Buy to Hold and Increased Target to $33 on, Tuesday, July 18th, 2023


These are the ratings of the 3 analyists that currently disagree with Salim


  • Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $38 on, Thursday, August 17th, 2023
  • Dane Leone of "Raymond James" Maintained at Buy with Increased Target to $46 on, Tuesday, July 18th, 2023
  • Paul Choi of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $50 on, Tuesday, July 18th, 2023